• BBC NewsJohnson & Johnson faces $417m payout in latest talc case

    Johnson & Johnson has been ordered to pay $417m (£323.4m) to a woman who says she developed ovarian cancer after using products such as baby powder.The California jury’s decision marks the largest award yet in a string of lawsuits that claim the firm did not adequately warn about cancer risks from talc-based products.A spokeswoman for Johnson & Johnson defended the Read more...

  • The Washington PostDoes talcum powder cause ovarian cancer?

    Does talcum powder cause ovarian cancer? A Los Angeles jury thinks so. This week it ordered Johnson & Johnson to pay $417 million to 63-year-old Eva Echeverria. She blamed her terminal illness on Johnson’s Baby Powder, which she used for decades starting at age 11. The company should have warned consumers about the risk, she argued. The jury award is Read more...

  • New York Times$417 Million Awarded in Suit Tying Johnson’s Baby Powder to Cancer

    In what may be the largest award so far in a lawsuit tying ovarian cancer to talcum powder, a Los Angeles jury on Monday ordered Johnson & Johnson to pay $417 million in damages to a medical receptionist who developed ovarian cancer after using the company’s trademark Johnson’s Baby Powder on her perineum for decades.Eva Echeverria, 63, of East Los Read more...

  • The IndependentKathy Bates was told to keep her cancer diagnosis secret in case it hurt her career

    Kathy Bates has stated she was warned against revealing her cancer diagnosis under the belief it would damage her career.  “Back in 2003, when I had ovarian cancer, my agent told me not to tell anyone about it,” she told WebMD. “Even my gynecologist, whose husband worked in the business, warned that I shouldn’t come out with it because of the Read more...

  • ReutersClovis's ovarian cancer drug set for label expansion, shares soar

    n”Positive late-stage data on Clovis Oncology Inc’s ovarian cancer drug, Rubraca, could help widen the use of the therapy and differentiate it from rivals, the U.S. biotech said on Monday, sending its shares soaring 48 percent.The drug, like Tesaro Inc’s Zejula and AstraZeneca Plc’s Lynparza, belongs to a closely watched class of new medicines called PARP inhibitors, which blocks enzymes Read more...